Method for Detecting Chronic Myelogenous Leukemia Cells

检测慢性粒细胞白血病细胞的方法

• 批准号: 6545515
• 负责人: JAN TRNOVSKY
• 金额: $ 16.46万
• 依托单位: ONE CELL SYSTEMS, INC
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-08-26 至 2003-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6545515
• 关键词: cell line; chromosome translocation; chronic myelogenous leukemia; cytodiagnosis; diagnosis design /evaluation; flow cytometry; fluorescent in situ hybridization; messenger RNA; minimal residual disease; neoplasm /cancer diagnosis; oligonucleotides; technology /technique development

DESCRIPTION (provided by applicant): Chronic myelogenous leukemia (CML) is characterized by a t(9;22) chromosomal translocation, which results in a fusion gene whose protein product shows enhanced tyrosine kinase activity. This fusion protein is a target in a new promising treatment using a Bcr-Abl kinase inhibitor. CML is typically detected using either slide-based fluorescence in situ hybridization (FISH) to detect the translocation, or reverse transcriptase-polymerase chain reaction (RT-PCR) to detect the fusion mRNA transcript. FISH is labor-intensive and cannot easily detect rare cancer cells. RT-PCR is susceptible to contamination and false positive results. This Phase I research proposes to develop a novel assay format for detecting CML positive cells. Use of flow cytometry will permit analysis of at least a million cells per hour, and identification of rare cancer cells. PROPOSED COMMERCIAL APPLICATION: This assay will facilitate post-treatment patient monitoring and early detection of minimal residual disease (MRD).

描述（由申请人提供）： 慢性骨髓性白血病（CML）的特征是T（9; 22）染色体易位，这导致融合基因的蛋白质产物显示出增强的酪氨酸激酶活性。该融合蛋白是使用BCR-ABL激酶抑制剂进行新的有前途治疗的靶标。通常使用基于幻灯片的荧光原位杂交（FISH）检测CML以检测易位或逆转录酶 - 聚合酶链反应（RT-PCR）以检测融合mRNA转录本。鱼是劳动密集型的，无法轻易检测到稀有的癌细胞。 RT-PCR容易受到污染和假阳性结果。该阶段I研究提出了一种用于检测CML阳性细胞的新型测定格式。流式细胞仪的使用将允许每小时至少一百万个单元格分析，并识别 罕见的癌细胞。 拟议的商业应用： 该测定法将促进治疗后的患者监测和早期检测最少残留疾病（MRD）。